Back to search

Peptide record

TPDB10626

MSP-4 TP4 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
25 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10626
MSP-4 TP4
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb AI4AVP dbAMP 3.0 DRAVP 2.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 25-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FIHHIIGGLFSAGKAIHRLIRRRRR
Physicochemical Analysis
C135H226N50O27
NDCEQMPTWYV
R
2981.60
13.10
10
0
11
+7
3.62
-0.128
117.20
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
2
A
6
R
0
N
0
D
0
C
0
E
0
Q
3
G
3
H
5
I
2
L
1
K
0
M
2
F
0
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 6 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 3 I: 5 L: 2 K: 1 M: 0 F: 2 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
25
C135H226N50O27
2981.60
13.10
+7
3.62
-0.128
Free
L
Linear
Free
Antimicrobial
Oreochromis niloticus
Evidence Records 55 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.03 µg/mL

Target

V. vulnificus 204

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aerugin
Evidence 2 Activity

Activity

MIC
Antibacterial
1.05 µg/mL

Target

A. hydrophila BCRC 13018

Source & Reference

dbAMP DRAMP

Other

Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-posit
Evidence 3 Activity

Activity

MIC
Antibacterial
0.03 µg/mL

Target

V. alginolyticus

Source & Reference

dbAMP DRAMP

Other

m-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC
Evidence 4 Activity

Activity

MIC
Antibacterial
0.52 µg/mL

Target

Pseudomonas aeruginosa ATCC 19660

Source & Reference

dbAMP DRAMP

Other

.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.
Evidence 5 Activity

Activity

MIC
Antibacterial
2.1 µg/mL

Target

Streptococcus agalactiae 819

Source & Reference

dbAMP DRAMP

Other

ticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml).
Evidence 6 Activity

Activity

MIC
Antibacterial
8.39 µg/mL

Target

Enterococcus faecalis BCRC 10066

Source & Reference

dbAMP DRAMP

Other

sa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml). It also inhibited the growth of multidru
Evidence 7 Activity

Activity

MIC
Antibacterial
5 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

tide was also reported by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM),
Evidence 8 Activity

Activity

MIC
Antibacterial
1.7 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4
Evidence 9 Activity

Activity

MIC
Antibacterial
20 µM

Target

E. tarda

Source & Reference

dbAMP DRAMP

Other

t S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4 is also called MSP-4 ( Kuo et al., 2018 ). This peptide may a
Evidence 10 Activity

Activity

IC50
IC50 = 5.03 µM
Anticancer
5.03 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2016

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 11 Activity

Activity

IC50
IC50 = 5.03 µM
Anticancer
5.03 µM

Target

Breast Cancer
MDA-MB-453
Breast

Assay & Model

MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2016
Evidence 12 Activity

Activity

IC50
IC50 = 5.03 µM
Anticancer
5.03 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTS assay
6-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2016
Evidence 13 Activity

Activity

LDH activity
LDH activity = 1.5mU/mL at 10 µg/mL
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

LDH leakage assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2016
Evidence 14 Activity

Activity

Cell viability
Cell viability = 26.78 ± 1.75% at 10 µM
Anticancer

Target

Bone Cancer
MG-63
Bone

Assay & Model

MTT assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 15 Activity

Activity

LD50
LD50 = 20 µg/mL
Anticancer
20 µg/mL

Target

Brain Tumor
U87-MG
Brain

Assay & Model

MTS/PMS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 16 Activity

Activity

LD50
LD50 = 20 µg/mL
Anticancer
20 µg/mL

Target

Brain Tumor
U-251
Brain

Assay & Model

MTS/PMS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 17 Activity

Activity

IC50
IC50 = 29.20 µg/mL
Anticancer
29.20 µg/mL

Target

Synovial Sarcoma
SW982
Muscle

Assay & Model

MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2021
Evidence 18 Activity

Activity

IC50
IC50 = 32.41 µg/mL
Anticancer
32.41 µg/mL

Target

Synovial Sarcoma
Aska-SS
Muscle

Assay & Model

MTS assay

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP
CancerPPD2
2021
Evidence 19 Activity

Activity

MIC
Antifungal
0.03 µg/mL

Target

V. vulnificus 204

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aerugin
Evidence 20 Activity

Activity

MIC
Antifungal
1.05 µg/mL

Target

A. hydrophila BCRC 13018

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-posit
Evidence 21 Activity

Activity

MIC
Antifungal
0.03 µg/mL

Target

V. alginolyticus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

m-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC
Evidence 22 Activity

Activity

MIC
Antifungal
0.52 µg/mL

Target

Pseudomonas aeruginosa ATCC 19660

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.
Evidence 23 Activity

Activity

MIC
Antifungal
2.1 µg/mL

Target

Streptococcus agalactiae 819

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml).
Evidence 24 Activity

Activity

MIC
Antifungal
8.39 µg/mL

Target

Enterococcus faecalis BCRC 10066

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

sa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml). It also inhibited the growth of multidru
Evidence 25 Activity

Activity

MIC
Antifungal
5 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

tide was also reported by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM),
Evidence 26 Activity

Activity

MIC
Antifungal
1.7 µM

Target

B. subtilis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4
Evidence 27 Activity

Activity

MIC
Antifungal
20 µM

Target

E. tarda

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

t S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4 is also called MSP-4 ( Kuo et al., 2018 ). This peptide may a
Evidence 28 Activity

Activity

MIC
Antiparasitic
0.03 µg/mL

Target

V. vulnificus 204

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aerugin
Evidence 29 Activity

Activity

MIC
Antiparasitic
1.05 µg/mL

Target

A. hydrophila BCRC 13018

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-posit
Evidence 30 Activity

Activity

MIC
Antiparasitic
0.03 µg/mL

Target

V. alginolyticus

Source & Reference

dbAMP 3.0 DRAMP

Other

m-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC
Evidence 31 Activity

Activity

MIC
Antiparasitic
0.52 µg/mL

Target

Pseudomonas aeruginosa ATCC 19660

Source & Reference

dbAMP 3.0 DRAMP

Other

.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.
Evidence 32 Activity

Activity

MIC
Antiparasitic
2.1 µg/mL

Target

Streptococcus agalactiae 819

Source & Reference

dbAMP 3.0 DRAMP

Other

ticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml).
Evidence 33 Activity

Activity

MIC
Antiparasitic
8.39 µg/mL

Target

Enterococcus faecalis BCRC 10066

Source & Reference

dbAMP 3.0 DRAMP

Other

sa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml). It also inhibited the growth of multidru
Evidence 34 Activity

Activity

MIC
Antiparasitic
5 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP

Other

tide was also reported by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM),
Evidence 35 Activity

Activity

MIC
Antiparasitic
1.7 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4
Evidence 36 Activity

Activity

MIC
Antiparasitic
20 µM

Target

E. tarda

Source & Reference

dbAMP 3.0 DRAMP

Other

t S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4 is also called MSP-4 ( Kuo et al., 2018 ). This peptide may a
Evidence 37 Activity

Activity

MIC
Antiviral
0.03 µg/mL

Target

V. vulnificus 204

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aerugin
Evidence 38 Activity

Activity

MIC
Antiviral
1.05 µg/mL

Target

A. hydrophila BCRC 13018

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against Gram-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-posit
Evidence 39 Activity

Activity

MIC
Antiviral
0.03 µg/mL

Target

V. alginolyticus

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

m-negative V. vulnificus 204 (MIC 0.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC
Evidence 40 Activity

Activity

MIC
Antiviral
0.52 µg/mL

Target

Pseudomonas aeruginosa ATCC 19660

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

.03 ug/ml), A. hydrophila BCRC 13018 (MIC 1.05 ug/ml), V. alginolyticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.
Evidence 41 Activity

Activity

MIC
Antiviral
2.1 µg/mL

Target

Streptococcus agalactiae 819

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

ticus (MIC 0.03 ug/ml), P. aeruginosa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml).
Evidence 42 Activity

Activity

MIC
Antiviral
8.39 µg/mL

Target

Enterococcus faecalis BCRC 10066

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

sa ATCC 19660 (MIC 0.52 ug/ml), Gram-positive bacteria S. agalactiae 819 (MIC 2.1 ug/ml), E. faecalis BCRC 10066 (MIC 8.39 ug/ml), and S. agalactiae BCRC 10787 (MIC: 0.13 ug/ml). It also inhibited the growth of multidru
Evidence 43 Activity

Activity

MIC
Antiviral
5 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

tide was also reported by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM),
Evidence 44 Activity

Activity

MIC
Antiviral
1.7 µM

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

by Acosta et al., 2013 and named Oreoch-2, which is active against S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4
Evidence 45 Activity

Activity

MIC
Antiviral
20 µM

Target

E. tarda

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

t S. aureus (MIC 5 uM), B. subtilis (MIC 1.7 uM), P. aeruginosa (6.7 uM), E. coli (5 uM), E. tarda (MIC 20 uM), C. albicans (26.7 uM). TP4 is also called MSP-4 ( Kuo et al., 2018 ). This peptide may a
Evidence 46 Activity

Activity

100% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 100 | µg/mL | target cell: Tilapia erythrocytes

Target

Tilapia erythrocytes

Source & Reference

NA
DBAASP
Five different piscidins from Nile tilapia, Oreochromis niloticus: analysis of their expressions and biological functions. | PLoS One | 2012
Evidence 47 Activity

Activity

100% Hemolysis
Toxicity
12.5 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 12.5 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Five different piscidins from Nile tilapia, Oreochromis niloticus: analysis of their expressions and biological functions. | PLoS One | 2012
Evidence 48 Activity

Activity

50% Cell death
Toxicity
20 µg/mL
Cytotoxic
50% Cell death | 20 | µg/mL | target cell: Tilapia ovary TO2 cells

Target

Tilapia ovary TO2 cells

Source & Reference

NA
DBAASP
Five different piscidins from Nile tilapia, Oreochromis niloticus: analysis of their expressions and biological functions. | PLoS One | 2012
Evidence 49 Activity

Activity

50% Cytotoxicity
Toxicity
9.7±1.5 µg/mL
Cytotoxic
50% Cytotoxicity | 9.7±1.5 | µg/mL | target cell: Baby Hamster Kidney cells BHK-21

Target

Baby Hamster Kidney cells BHK-21

Source & Reference

NA
DBAASP
Grouper (Epinephelus coioides) antimicrobial peptide epinecidin-1 exhibits antiviral activity against foot-and-mouth disease virus in vitro. | Peptides | 2018
Evidence 50 Activity

Activity

50% Hemolysis
Toxicity
19 µM
Hemolytic Cytotoxic
50% Hemolysis | 19 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cloning and functional characterization of three novel antimicrobial peptides from tilapia (Oreochromis niloticus). | Aquaculture | 2013
Evidence 51 Activity

Activity

57% Hemolysis
Toxicity
57 µM
Hemolytic Cytotoxic
57% Hemolysis | 57 | µM | target cell: Tilapia erythrocytes

Target

Tilapia erythrocytes

Source & Reference

NA
DBAASP
Cloning and functional characterization of three novel antimicrobial peptides from tilapia (Oreochromis niloticus). | Aquaculture | 2013
Evidence 52 Activity

Activity

50% Hemolysis
Toxicity
4.5 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 4.5 | µg/mL | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Hydrophobic residues are critical for the helix-forming, hemolytic and bactericidal activities of amphipathic antimicrobial peptide TP4. | PLoS One | 2017
Evidence 53 Activity

Activity

40.33% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
40.33% Hemolysis | 64 | µg/mL | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Rational design and synthesis of Oreoch-2 analogues as efficient broad-spectrum antimicrobial peptides | Bioorg Chem | 2021
Evidence 54 Activity

Activity

% Hemolysis
Toxicity
2 %
Hemolytic
Hemolytic_activity: [Ref.29040295] 2% hemolysis at 0.78 µg/ml, 5% hemolysis at 1.56 µg/ml, 45% hemolysis at 3.13 µg/ml, 85% hemolysis at 6.25 µg/ml, 98% hemolysis at 12.50 µg/ml, 100% hemolysis at 25.00 µg/ml against mouse red blood cell

Target

erythrocytes

Source & Reference

NA
DRAMP
PLoS One. 2017 Oct 17 12(10):e0186442.
Evidence 55 Hemolysis

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.